Accès ouvert
2025
article
OpenAlex
Xuan Fan, Chaonan Li, Hui Zhao, Na Liu et autres
Background: Cytomegalovirus (CMV), an opportunistic pathogen, can cause severe pneumonia in Chronic myeloid leukemia (CML) children undergoing hematopoietic stem cell transplantation (HSCT), resulting in a high mortality rate. Case presentation: An 11-year-old girl was hospitalized with a 3-day history of fever and …
cn
(code pays fourni par la source)
Accès ouvert
2025
review
OpenAlex
Na Liu, Baowanze Zhang, Jiali He, Li Su
Objective: Significant efficacy heterogeneity exists between first- and second-line immunotherapy regimens for advanced squamous non-small cell lung cancer (SqNSCLC), but most regimens lack directly comparable clinical trial evidence, resulting in unclear prioritization. This analysis identifies optimal treatment strategies by evaluating differences in …
cn
(code pays fourni par la source)
2025
article
OpenAlex
Xindi Huang, Jian Wu, Yalan Wang, Jingping Yu et autres
cn
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Shuaibing Hou, Xiaomin Wang, Tengxiao Guo, Yanjie Lan et autres
Acute myeloid leukemia (AML) is a major hematopoietic malignancy characterized by the accumulation of immature and abnormally differentiated myeloid cells in bone marrow. Here with in vivo and in vitro models, we demonstrate that the Plant homeodomain finger gene 6 (PHF6) plays …
cn, Éthiopie
(code pays fourni par la source)
2023
other
OpenAlex
Yuxin Wang, Yao Sun, Jing Xie, Na Liu et autres
OBJECTIVE: To evaluate the efficacy and safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with decitabine (Dec)-conditioning regimen in the treatment of myelodysplastic syndrome (MDS) and MDS transformed acute myeloid leukemia (MDS-AML). METHODS: /d×3 d). RESULTS: =0.019). CONCLUSION: Allo-HSCT with Dec-conditioning regimen …
cn
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Cheng-Long Hu, Bingyi Chen, Zijuan Li, Tianbiao Yang et autres
Aberrant self-renewal of leukemia initiation cells (LICs) drives aggressive acute myeloid leukemia (AML). Here, we report that UHRF1, an epigenetic regulator that recruits DNMT1 to methylate DNA, is highly expressed in AML and predicts poor prognosis. UHRF1 is required for myeloid leukemogenesis …
cn
(code pays fourni par la source)
Accès ouvert
2022
preprint
OpenAlex
Weiping Yuan, Shuaibing Hou, Xiaomin Wang, Tengxiao Guo et autres
cn, Éthiopie
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Yifan Zhang, Chunhui Xu, Na Liu, Ling Zhang et autres
The ETO-family transcriptional corepressors, including ETO, ETO2, and MTGR1, are all involved in leukemia-causing chromosomal translocations. In every case, an ETO-family corepressor acquires a DNA-binding domain (DBD) to form a typical transcription factor-the DBD binds to DNA, while the ETO moiety manifests …
cn, us
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Zuxin Li, Chengming Xia, Yi Tian, Beilei Zhang et autres
The analysis and detection of nucleic acid and specific antigens and antibodies are the most basic technologies for virus monitoring. However, the potential window for applying these technologies exists within a late specific period in the early monitoring and control of unknown …
cn
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Yuxin Wang, Yao Sun, Jing Xie, Jiangwei Hu et autres
Myelodysplastic syndrome (MDS) with TP53 mutations has a poor prognosis after transplantation, and novel therapeutic means are urgently needed. Decitabine (Dec) monotherapy has demonstrated improved overall response rates in MDS and acute myeloid leukaemia, although these responses were not durable. This study …
cn
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Tao Tu, Biao Li, Xuping Li, Baojian Zhang et autres
cn
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Yuhang Li, Longcan Cheng, Xu Chen, Jianlin Chen et autres
Hypomethylating agents, decitabine (DAC) and azacitidine, can act as prophylactic and pre-emptive approaches after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and a non-intensive bridging approach before allo-HSCT. However, they are rarely used as a part of conditioning regimens in patients with relapsed …
cn
(code pays fourni par la source)